Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 5/20 | 0.51 |
| ▸ | MAOB | P27338 | 5/20 | 0.43 |
| ▸ | MAOA | P21397 | 4/20 | 0.43 |
| ▸ | F12 | P00748 | 5/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4513642 | 0.90 | S1PR1 (0.48) | S1PR1MAOBMAOAF12MAPT | |
| SCHEMBL3885669 | 0.87 | S1PR1 (0.64) | S1PR1MAOBMAOAMAPTTP53 | |
| SCHEMBL3997597 | 0.87 | S1PR1 (0.46) | S1PR1MAOBMAOAF12MAPT | |
| SCHEMBL4510541 | 0.87 | S1PR1 (0.51) | S1PR1MAOBMAOAF12MAPT | |
| SCHEMBL4534562 | 0.87 | S1PR1 (0.54) | S1PR1MAOBMAOAMAPTTP53 | |
| SCHEMBL3947945 | 0.86 | S1PR1 (0.53) | S1PR1MAOBMAOAF12MAPT | |
| SCHEMBL4520770 | 0.84 | MAOA (0.46) | MAOBMAOAF12MAPTTP53 | |
| SCHEMBL4518093 | 0.84 | S1PR1 (0.58) | S1PR1MAOBMAOAMAPTTP53 | |
| SCHEMBL3947827 | 0.84 | S1PR1 (0.51) | S1PR1MAOBMAOAMAPTTP53 | |
| SCHEMBL3879717 | 0.84 | S1PR1 (0.51) | S1PR1MAOBMAOAF12MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090318546-A1 | Chromen-2-One Derivatives | NOVARTIS AG (CH) | 2009-12-24 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318546-A1 | Chromen-2-One Derivatives | CYP1A2, CYP4B1, CYP1B1 | S1PR1 3084/4885MAOB 1375/4885MAOA 1782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.